ArticleFrontiers in neurology2021
Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in Men.
Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05442008 (Study of Early MIDAS Reduction at 3 Months as Predictor of Long-term Erenumab Treatment in Chronic Migraine), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of Early MIDAS Reduction at 3 Months as Predictor of Long-term Erenumab Treatment in Chronic Migraine: a Real-life, Open-label, Trial
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Sex-specific management of migraine a systematic review and consensus statement from the European Headache Federation (EHF).The journal of headache and pain · 2026Pooled it
- Pooled it
- Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.The journal of headache and pain · 2022Trial
- Sex-specific considerations in migraine therapy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Sex differences in the real-world use of rimegepant for short-term prevention of migraine in the United States.Frontiers in neurology · 2026Observational
- Sex-related disparities in migraine recognition and management: insights from a tertiary headache center cohort.The journal of headache and pain · 2025Article
- Migraine in men.The journal of headache and pain · 2025Review
- Treatment Patterns and Healthcare Resource Utilization by Gender and Migraine Frequency in Adult Patients Receiving Galcanezumab Versus Standard of Care Preventive Medications Over 24 months: A United States Retrospective Claims Study.Patient preference and adherence · 2025Article
- Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence.Brain sciences · 2024Review
- Toxicokinetics of a humanized anti-cocaine monoclonal antibody in male and female rats and lack of cross-reactivity.Human vaccines & immunotherapeutics · 2023Review
- A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients.The journal of headache and pain · 2022Article
- Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review.Current pain and headache reports · 2022Review
- Sex Differences in Chronic Migraine: Focusing on Clinical Features, Pathophysiology, and Treatments.Current pain and headache reports · 2022Review
- Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study.The journal of headache and pain · 2022Article
- Cranial autonomic symptoms and response to monoclonal antibodies targeting the Calcitonin gene-related peptide pathway: A real-world study.Frontiers in neurology · 2022Article
- Spinal cord injury-induced neurogenic bowel: A role for host-microbiome interactions in bowel pain and dysfunction.Neurobiology of pain (Cambridge, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 19 institutions in 6 countries.
Raffaele OrnelloNeuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy.
Carlo BaraldiDepartment of Biomedical, Metabolic and Neural Sciences, School in Neurosciences, University of Modena and Reggio Emilia, Modena, Italy.
Simona GuerzoniMedical Toxicology - Headache and Drug Abuse Research Center, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Giorgio LambruThe Headache Service, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London, United Kingdom.
Matteo FuccaroThe Headache Service, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London, United Kingdom.
Bianca RaffaelliDepartment of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Astrid GendollaPraxis Gendolla, Essen, Germany.
Piero BarbantiHeadache and Pain Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele, Rome, Italy.
Cinzia AuriliaHeadache and Pain Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele, Rome, Italy.
Sabina CevoliIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Valentina FavoniIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Fabrizio VernieriHeadache and Neurosonology Unit, Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Claudia AltamuraHeadache and Neurosonology Unit, Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Antonio RussoHeadache Center, Department of Medical, Surgical, Neurological, Metabolic, and Aging Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Marcello SilvestroHeadache Center, Department of Medical, Surgical, Neurological, Metabolic, and Aging Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Elisabetta Dalla ValleHeadache Centre, Ospedale S. Antonio Abate, ASST Valle Olona, Gallarate, Italy.
Andrea MancioliHeadache Centre, Ospedale S. Antonio Abate, ASST Valle Olona, Gallarate, Italy.
Angelo RanieriHeadache Centre, Division of Neurology and Stroke Unit, "A. Cardarelli" Hospital, Naples, Italy.
Gennaro AlfieriHeadache Centre, Division of Neurology and Stroke Unit, "A. Cardarelli" Hospital, Naples, Italy.
Nina LatyshevaSechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Elena FilatovaSechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Jamie TalbotSouthwest Neurology Audit and Research Group, Department of Neurology, Derriford Hospital, Plymouth, United Kingdom.
Shuli ChengDepartment of Neurology, Alfred Health, Melbourne, VIC, Australia.
Dagny HolleDepartment of Neurology, West German Headache Center, University Hospital Essen, Essen, Germany.
Armin SchefflerDepartment of Neurology, West German Headache Center, University Hospital Essen, Essen, Germany.
Tomáš NežádalDepartment of Neurology, Military University Hospital Prague, First Faculty of Medicine Charles University, Prague, Czechia.
Dana ČtrnáctáDepartment of Neurology, Military University Hospital Prague, First Faculty of Medicine Charles University, Prague, Czechia.
Jitka ŠípkováDepartment of Neurology, Military University Hospital Prague, First Faculty of Medicine Charles University, Prague, Czechia.
Zuzana MatoušováDepartment of Neurology, Motol University Hospital Prague, First Faculty of Medicine Charles University, Prague, Czechia.
Lucia SetteNeuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy.
Alfonsina CasalenaDepartment of Neurology, "G. Mazzini" Hospital, Teramo, Italy.
Maurizio MaddestraDepartment of Neurology, "F. Renzetti" Hospital, Chieti, Italy.
Stefano ViolaDepartment of Neurology, "S. Pio da Pietrelcina" Hospital, Chieti, Italy.
Giannapia AffaitatiHeadache Center, Geriatrics Clinic, Department of Medicine and Science of Aging and Center for Advanced Studies and Technology, G. D'Annunzio University, Chieti, Italy.
Maria Adele GiamberardinoHeadache Center, Geriatrics Clinic, Department of Medicine and Science of Aging and Center for Advanced Studies and Technology, G. D'Annunzio University, Chieti, Italy.
Francesca PistoiaNeuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy.
Uwe ReuterThe Headache Service, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London, United Kingdom.
Simona SaccoNeuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy.
University of L'Aquila · ITCharles University · CZAzienda Ospedaliera Sant’Antonio Abate di Gallarate · ITCampus Bio Medico University Hospital · ITFatebenefratelli Hospital · ITGuy's and St Thomas' NHS Foundation Trust · GBIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituto delle Scienze Neurologiche di Bologna · ITSechenov University · RUUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Chieti-Pescara · ITUniversity of Modena and Reggio Emilia · ITWest German Heart and Vascular Center Essen · DEAlfred Health · AUCharité - Universitätsmedizin Berlin · DEDerriford Hospital · GBMilitary University Hospital Prague · CZNational Health Service · GBOspedale "Floraspe Renzetti" · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
erenumabgendermenmigrainemigraine treatmentreal-world evidence
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT05442008ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.